论文部分内容阅读
去甲长春花碱(Navelbine,NVB)为半合成的长春碱类抗肿瘤新药,抗瘤谱广。单药NVB在NSCLC治疗中显示突出疗效。我们科从1995年12月～1997年12月,应用去甲长春花碱(NVB)加卡铂(Carboplatin)联合化疗治疗晚期NSCLC36例,疗效满意,现将结果报告如下: 1 资料与方法 1.1 病例选择:36例由病理证实的晚期NSCLC;近1个月未接触抗肿瘤治疗:治疗前肝肾功能、血象正常。应用可测量的临床或X线指标评价近期疗效。男性29例,女性7例。男女比例4.1:1。年龄范围33～72岁,中位年龄58岁。初治者20例,复治者16例。腺癌24例。鳞癌12例。按照UICC-TNM分期:Ⅲ_b期24例,Ⅳ期12例。 1.2 治疗方法:NVB30mg/m~2静脉注入,第1,8天;卡
Navelbine (Navelbine, NVB) is a semi-synthetic vinblastine antitumor drug with a broad spectrum of antitumor activity. Single-agent NVB shows outstanding efficacy in the treatment of NSCLC. In our department from December 1995 to December 1997, 36 patients with advanced NSCLC treated with vinorelbine (NVB) combined with carboplatin were treated with satisfactory results. The results are reported as follows: 1 Materials and methods 1.1 Cases Selection: 36 cases of advanced NSCLC confirmed by pathology; no contact with anti-tumor therapy in the past 1 month: liver and kidney function, normal blood before treatment. Applicable measurable clinical or radiological indicators to evaluate short-term efficacy. There were 29 males and 7 females. The male to female ratio is 4.1:1. The age range is from 33 to 72 years old and the median age is 58 years old. There were 20 cases of untreated persons and 16 cases of retreatment. Adenocarcinoma in 24 cases. Squamous cell carcinoma in 12 cases. According to UICC-TNM staging: 24 cases of III_b period and 12 cases of IV period. 1.2 Treatment: NVB 30mg/m~2 intravenous injection, 1st and 8th days; card